Dr Ann McCormack
Dr McCormack completed her PhD studies at the Kolling Institute of Medical Research examining the role of MGMT (06-methylguanine-DNA methyltransferase) as a biomarker of response to temozolomide (a novel therapy for aggressive pituitary tumours) and exploring its role in pituitary tumorigenesis. She was awarded the 2008 Endocrine Society of Australia Bryan Hudson Clinical Endocrinology Award and has been invited to present her work at the 2009 American Endocrine Society Annual Scientific Meeting and 2012 International Congress of Endocrinology in Italy.
During 2010, she also undertook a research and clinical fellowship at the Oxford Centre for Diabetes, Endocrinology and Metabolism in the UK, a centre with an international reputation for expertise in pituitary disease and neuroendocrine tumours. She has recently been awarded the 2013 John Shine Translational Research Fellowship at the Garvan Institute. Dr McCormack also holds a 3 year tenure as Chair of the Program Organising Committee for the Endocrine Society of Australia’s Annual Scientific Meeting.
Dr McCormack is a staff specialist in the Department of Endocrinology at St Vincent’s Hospital and holds a conjoint position at the Garvan Institute of Medical Research and The University of New South Wales. Her primary research interest is in the field of pituitary tumour biology, in particular aggressive pituitary tumours and familial pituitary tumours.
In the NewsRecipients of the 2013 John Shine Translational Research Fellowship Announced - Nov 05, 2012
What pituitary tumours may tell us about the biology of other cancers - Jul 27, 2012
Awards and Honours
Endocrine Society of Australia International Travel Award (2010)
Endocrine Society of Australia Bryan Hudson Clinical Endocrinology Award (2008)
Cancer Institute of NSW Research Scholar Award (2007)
NHMRC Medical Postgraduate Scholarship (2006)
Northern Clinical School Registrar Teaching Award (2005)
MBBS (Hons 1) 1999
De Sousa SMC, Earls P, McCormack AI. Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition. Endocrinol Diabetes Metab Case Rep. 2015; May 2015:150017. doi: 10.1530/EDM-15-0017.
Naziat A, Karavitaki N, Thakker R, Ansorge O, Sadler G, Gleeson F, Cranston T, McCormack A, Grossman AB, Shine B. Confusing genes: a patient with MEN2A and Cushing’s disease. Clin Endocrinol 2013; 78(6):966-8.
McCormack A et al. MGMT expression and pituitary tumours: relationship to tumour biology. Pituitary 2013; 16(2):208-19.
Greenfield, JR and McCormack, AI. Medication to prevent breast cancer – too much to swallow? Med J Aust 2012; 196(5):314.
McCormack, AI et al. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 2011; 41(10):1133-48.
Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010; 163(6):843-51.
McCormack, AI et al. Low 06-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol 2009; 71(2):226-33.